| Jennifer Listerman, MD | |
|
613 23rd St, Suite 230, Ashland, KY 41101-2878 | |
| (606) 324-4745 | |
| (606) 324-4941 |
| Full Name | Jennifer Listerman |
|---|---|
| Gender | Female |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 20 Years |
| Location | 613 23rd St, Ashland, Kentucky |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1568519361 | NPI | - | NPPES |
| 7100140590 | Medicaid | KY | |
| 3810019206 | Medicaid | WV | |
| 3112081 | Medicaid | OH |
| Facility Name | Location | Facility Type |
|---|---|---|
| King's Daughters' Medical Center | Ashland, KY | Hospital |
| Kings Daughters Medical Center Ohio | Portsmouth, OH | Hospital |
| Three Rivers Medical Center | Louisa, KY | Hospital |
| Southern Ohio Medical Center | Portsmouth, OH | Hospital |
| St Mary's Medical Center | Huntington, WV | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kings Daughters Medical Specialties Inc | 6103968029 | 328 |
| Kings Daughters Medical Specialties Inc | 6103968029 | 328 |
News Archive
Noile-Immune Biotech Inc., ("Noile-Immune") and C4U Corporation, ("C4U") announced that they have entered into an agreement on joint research and commercialization of next-generation allogeneic gene-modified immune cell therapy combining C4U's CRISPR/Cas3 genome editing technology and Noile-Immune's PRIME (Proliferation inducing and migration enhancing) technology designed to improve proliferation and trafficking of immune cells into solid tumors.
Allscripts today introduced the Allscripts Stimulus Program, making it safe and easy for physicians to purchase and rapidly deploy Electronic Health Records that will qualify for significant federal incentives.
The Boston Globe: "A Suffolk Superior Court judge yesterday denied a request that would have let six Massachusetts health insurers go forward with double-digit rate hikes for tens of thousands of small businesses and individuals, setting up a protracted battle that could become a test of government's role in controlling health care costs.
The European Commission today launched the largest-ever collaborative tuberculosis (TB) initiative for World TB-day, March 24. Fifty-two research teams from academia and industry from 15 European and African countries are joining forces with the European Commission to help eradicate TB. Globally, TB kills 2 million people a year, with one-third of the world's population currently infected with the bacillus, Mycobacterium tuberculosis (Mtb). While most cases and deaths occur in developing countries, resistant Mtb strains are mainly found among the poorest people in developed countries, as incomplete treatment increases drug resistance. The European Union is confronting the re-emerging threat of TB by investing €32 million in two overlapping research projects. This cash will be used in an accelerated effort to develop new, effective vaccines to fight TB.
The health of the surrounding tissue affects the success of a dental implant. Identifying and reducing risk factors is therefore a key step in the implant process. Now a combination of genes has been identified as a possible indicator of greater tissue destruction leading to negative outcomes for implants.
› Verified 5 days ago
| Entity Name | Kings Daughters Medical Specialties Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710215736 PECOS PAC ID: 6103968029 Enrollment ID: O20100217000538 |
News Archive
Noile-Immune Biotech Inc., ("Noile-Immune") and C4U Corporation, ("C4U") announced that they have entered into an agreement on joint research and commercialization of next-generation allogeneic gene-modified immune cell therapy combining C4U's CRISPR/Cas3 genome editing technology and Noile-Immune's PRIME (Proliferation inducing and migration enhancing) technology designed to improve proliferation and trafficking of immune cells into solid tumors.
Allscripts today introduced the Allscripts Stimulus Program, making it safe and easy for physicians to purchase and rapidly deploy Electronic Health Records that will qualify for significant federal incentives.
The Boston Globe: "A Suffolk Superior Court judge yesterday denied a request that would have let six Massachusetts health insurers go forward with double-digit rate hikes for tens of thousands of small businesses and individuals, setting up a protracted battle that could become a test of government's role in controlling health care costs.
The European Commission today launched the largest-ever collaborative tuberculosis (TB) initiative for World TB-day, March 24. Fifty-two research teams from academia and industry from 15 European and African countries are joining forces with the European Commission to help eradicate TB. Globally, TB kills 2 million people a year, with one-third of the world's population currently infected with the bacillus, Mycobacterium tuberculosis (Mtb). While most cases and deaths occur in developing countries, resistant Mtb strains are mainly found among the poorest people in developed countries, as incomplete treatment increases drug resistance. The European Union is confronting the re-emerging threat of TB by investing €32 million in two overlapping research projects. This cash will be used in an accelerated effort to develop new, effective vaccines to fight TB.
The health of the surrounding tissue affects the success of a dental implant. Identifying and reducing risk factors is therefore a key step in the implant process. Now a combination of genes has been identified as a possible indicator of greater tissue destruction leading to negative outcomes for implants.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jennifer Listerman, MD Po Box 2379, Ashland, KY 41105-2379 Ph: (606) 324-4745 | Jennifer Listerman, MD 613 23rd St, Suite 230, Ashland, KY 41101-2878 Ph: (606) 324-4745 |
News Archive
Noile-Immune Biotech Inc., ("Noile-Immune") and C4U Corporation, ("C4U") announced that they have entered into an agreement on joint research and commercialization of next-generation allogeneic gene-modified immune cell therapy combining C4U's CRISPR/Cas3 genome editing technology and Noile-Immune's PRIME (Proliferation inducing and migration enhancing) technology designed to improve proliferation and trafficking of immune cells into solid tumors.
Allscripts today introduced the Allscripts Stimulus Program, making it safe and easy for physicians to purchase and rapidly deploy Electronic Health Records that will qualify for significant federal incentives.
The Boston Globe: "A Suffolk Superior Court judge yesterday denied a request that would have let six Massachusetts health insurers go forward with double-digit rate hikes for tens of thousands of small businesses and individuals, setting up a protracted battle that could become a test of government's role in controlling health care costs.
The European Commission today launched the largest-ever collaborative tuberculosis (TB) initiative for World TB-day, March 24. Fifty-two research teams from academia and industry from 15 European and African countries are joining forces with the European Commission to help eradicate TB. Globally, TB kills 2 million people a year, with one-third of the world's population currently infected with the bacillus, Mycobacterium tuberculosis (Mtb). While most cases and deaths occur in developing countries, resistant Mtb strains are mainly found among the poorest people in developed countries, as incomplete treatment increases drug resistance. The European Union is confronting the re-emerging threat of TB by investing €32 million in two overlapping research projects. This cash will be used in an accelerated effort to develop new, effective vaccines to fight TB.
The health of the surrounding tissue affects the success of a dental implant. Identifying and reducing risk factors is therefore a key step in the implant process. Now a combination of genes has been identified as a possible indicator of greater tissue destruction leading to negative outcomes for implants.
› Verified 5 days ago
Padma Venkatraman, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 101 Ashland Dr, Ashland, KY 41101 Phone: 606-324-1996 Fax: 606-833-2430 | |
Amr Idris, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 613 23rd St Ste 230, Ashland, KY 41101 Phone: 606-324-4745 Fax: 606-324-4941 | |
Paula K Larsen, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 1000 Ashland Dr Ste G1, Ashland, KY 41101 Phone: 606-408-4900 Fax: 606-408-6643 | |
Michael Don Canty, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 617 23rd St, Suite 11, Ashland, KY 41101 Phone: 606-324-3188 Fax: 606-329-2237 | |
Dr. Ryann Acquino Pangan, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 613 23rd St Ste 130, Ashland, KY 41101 Phone: 606-329-9335 Fax: 606-324-6383 | |
Dr. Francisco Fernandez-gonzalez, Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 613 23rd St Ste 310, Ashland, KY 41101 Phone: 606-833-2161 | |
Dr. Chad Jacob Tarabolous, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 617 23rd St, Suite 19, Ashland, KY 41101 Phone: 606-325-2221 Fax: 606-324-1326 |